Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).

• Status: Not yet recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury.

The main questions it aims to answer are:

• If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg.

• If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Loma Linda University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Age ≥18

• All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission

Exclusion Criteria:

• Age <18

• Pregnant women

• No enteral route access for Aspirin administration

• Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed

• Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed

• Patients with BCVI grade 5 injury based on Biffl classification

• Presence of any contraindication or history of allergy to Aspirin

• Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging

• Patients with acute spinal trauma that needs surgical intervention